RTW Venture

Portfolio Company Update: Ventyx IPO
RNS Number : 8822P
RTW Venture Fund Limited
22 October 2021

LEI: 549300Q7EXQQH6KF7Z84

22 October 2021

RTW Venture Fund Limited

Portfolio Company Update: Ventyx IPO

Ventyx Prices Upsized $151.5 Million IPO

RTW Venture Fund Limited (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, is pleased to note the 20 October 2021 announcement by one of its portfolio companies, Ventyx Biosciences, Inc. ("Ventyx") regarding its pricing of an upsized $151.5 million initial public offering ("IPO") and admission to trade on Nasdaq Global Market under ticker "VTYX".

Ventyx is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases. Ventyx's pipeline programs include: (1) a selective allosteric TYK2 inhibitor for a broad range of immunological disorders, (2) a tissue selective S1P1R modulator for inflammatory bowel disease (IBD), and (3) a preclinical NLRP3 inhibitor program.

Prior to IPO, the Company, together with other funds managed by RTW Investments, LP (the "Investment Manager"), participated in Ventyx's $114 million financing round in March 2021.

Ventyx's IPO raised $151.5 million by offering c. 9.5 million shares at $16.00 per share. On the first day of trading, Ventyx's share price increased by 31.4% to close at $21.02 per share.

Stephanie Sirota, Chief Business Officer of the Investment Manager and Director of the Company, said:

"We are excited about Ventyx's successful IPO and look forward to supporting the company in its efforts to develop innovative therapeutics for patients with inflammatory and autoimmune diseases".

Ventyx's IPO pricing announcement can be accessed on its website at: www.ventyxbio.com, the full text of which is contained below.  


For Further Information

RTW Investments, LP                                     +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Senior Business Development Associate


Buchanan                                                          +44 (0)20 7466 5107
Charles Ryland

Henry Wilson

George Beale



About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund Limited invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.


Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced the pricing of its upsized initial public offering of 9,472,656 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Ventyx. In addition, Ventyx has granted the underwriters a 30-day option to purchase up to an additional 1,420,898 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ventyx, are expected to be approximately $151.5 million, excluding any exercise of the underwriters' option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on October 21, 2021 under the ticker symbol "VTYX." The offering is expected to close on October 25, 2021, subject to the satisfaction of customary closing conditions.

Jefferies, Evercore ISI and Piper Sandler are acting as joint book-running managers for the offering. LifeSci Capital is also acting as an underwriter for the offering. A registration statement relating to these securities became effective on October 20, 2021. The offering is made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; and Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx's clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact

Patti Bank Managing Director

Westwicke Partners

(415) 513-1284


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.